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Background: Neoadjuvant therapy for cancer of the esophagus or gastroesophageal (GE)-junction is well
established. The pros and cons of chemoradiotherapy and chemotherapy are debated. Chemoradiotherapy might
impair cardiac function eliciting postoperative morbidity. The aim of this pilot study was to describe acute changes
in left ventricular function following chemoradiotherapy or chemotherapy.
Methods: Patients with esophageal and (GE)-junction cancer enrolled at our center into a multicenter trial
comparing neoadjuvant chemoradiotherapy and chemotherapy were eligible. Patients were randomized to receive
cisplatin and 5-fluorouracil with or without the addition of 40 Gy radiotherapy prior to surgery. Left ventricular
function was evaluated using echocardiography and plasma N-Terminal Pro-B-Type Natriuretic Peptide (NT-proBNP)
before and after neoadjuvant treatment. The primary outcome measure was left ventricular global strain (GS). Clinical
effects were assessed using repeated exercise tests. Linear mixed models were used to analyze the effects of treatment
group, and the interaction between groups.
Results: 40 patients participated (chemoradiotherapy, n = 17; chemotherapy, n = 23). In the chemoradiotherapy group
there was no change in left ventricular global strain but mitral annular plane systolic excursion (MAPSE) of the
ventricular septum, early diastolic filling velocity (E-velocity), and the ratio of early to late ventricular filling
velocities (E/A ratio) decreased significantly (p = 0.02, p = 0.01, and p = 0.03, respectively). No changes were
observed in the chemotherapy group. There was a trend towards an interaction effect for MAPSE sept and E
(p = 0.09 and p = 0.09). NT-proBNP increased following chemoradiotherapy (p = 0.05) but not after chemotherapy
(p > 0.99), and there was a trend towards an interaction effect (p = 0.07). Working capacity decreased following
neoadjuvant treatment (chemoradiotherapy p = 0.001, chemotherapy p = 0.03) and was more pronounced after
chemoradiotherapy with a trend towards an interaction effect (p = 0.10).
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Conclusions: Neoadjuvant chemoradiotherapy but not chemotherapy before surgery for cancer of the esophagus
or GE-junction seems to induce an acute negative effect on both systolic and diastolic left ventricular function.
Future studies on neoadjuvant treatment for esophageal cancer are suggested to add measurements of cardiac
function.
Trial registration: Clinical Trials.gov NCT01362127.
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CardiotoxicityBackground
Neoadjuvant therapy has improved long-term survival
after esophagectomy for cancer of the esophagus or
gastroesophageal- (GE) junction even though long-term
results are still poor [1]. Currently both chemotherapy
and chemoradiotherapy are used. Two randomized trials
have addressed the advantage of one regimen over the
other [2,3]. Outcome results have, however, been criti-
cized either due to small sample size, slow recruitment
or lack of power to detect clinically relevant differences
in outcomes. Neoadjuvant chemoradiotherapy has been
suggested to increase postoperative mortality and possibly
also morbidity [4,2,5], although these concerns were not
confirmed according to other studies [6,7]. Currently it
appears that chemotherapy alone does not increase
postoperative morbidity or mortality while it is unclear
whether chemoradiotherapy do.
Radiation therapy directed towards a tumor in the
esophagus or GE-junction will inevitably irradiate the
heart. Long-term side effects of modern thoracic radio-
therapy include coronary artery disease and heart failure
[8], but little is known about acute cardiac effects.
Recent studies have demonstrated an acute decrease in
left ventricular systolic and diastolic function following
radiotherapy, but results are far from consistent [9-12].
Also N-Terminal Pro-B-Type Natriuretic Peptide (NT-
proBNP), widely used to diagnose and prognose heart
failure [13,14] has been observed to increase following
radiotherapy [15]. The incidence of postoperative cardiac
complications after esophagectomy is reported to be in
the range of 15-30% for both chemo-and chemoradio-
therapy [3,16,17].
The aim of this pilot study was to describe possible
acute effects of neoadjuvant therapy on left ventricu-
lar function using echocardiography and NT-proBNP
in patients with cancer of the esophagus or GE-junction.
The primary outcome variable was global systolic left
ventricular function measured as global strain (GS).
The secondary outcome variables were ejection frac-
tion (EF), regional systolic left ventricular function,
diastolic function and NT-proBNP. In addition, gen-
eral physical capacity was measured using repeated
exercise test.Patients and methods
Patient inclusion
A multicenter randomized trial of neoadjuvant chemo-
radiotherapy versus chemotherapy for cancer in the
esophagus or GE-junction was conducted between 2006
and 2013 in Sweden and Norway (NeoRes; EudraCTnr
2006-001785-16). The primary endpoint was the rate of
complete histological response in the surgical specimen,
which is a surrogate marker of improved long-term
survival. The study was designed to include 180 patients
based on a power calculation suggesting a sample size of
172 patients to achieve the primary endpoint assuming
an increase in rate of complete histological response
from 20% to 35% with a power of 80%. Inclusion criteria
were age 75 years or less, histologically verified squamous
cell carcinoma or adenocarcinoma of the esophagus or
GE-junction, tumor stage T1-3 and N0-1 (according to
AJCC TNM staging system 6th edition) [18], WHO per-
formance status 0–1 and no major illness making neoad-
juvant treatment unsuitable. Patients were stratified by
histology before randomization. Randomization was done
by a computer based program operational at the Regional
Oncological Center in Stockholm.
The data presented here originate from a cohort of pa-
tients within the NeoRes trial scheduled for surgery at
the Karolinska University Hospital. Patients underwent
an extended protocol with studies of heart function
which started in 2008. Added inclusion criteria were
planned thoracoabdominal surgery. The NeoRes study
protocol was approved by the regional ethics committee
(EPN Stockholm 2006/738-32) and was registered at the
registration site of the US National Institute of Health
(ClinicalTrials.gov NCT01362127). For the extended pro-
tocol additional ethics approval was obtained (amendment
2008/1822-32). All patients were given written and oral
information and were included after a signed informed
consent had been obtained.
Neoadjuvant treatment
Chemotherapy was given in three cycles of 21 days. Cis-
platin 100 mg/m2 was given on day 1 and 5-fluorouracil
750 mg/m2/24 hrs was given on days 1–5. Cisplatin was
switched to carboplatin or oxaliplatin in case of hearing
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allowed for side effects. In the chemoradiotherapy group,
concomitant radiotherapy was administered during cy-
cles two and three with a total dose of 40 Gy; 2 Gy/day,
5 fractions per week. Radiotherapy was planned using a
computer tomography-based three-dimensional treatment
planning system (EclipseTM, Varian Medical systems, Palo
Alto, USA). Treatment was administered using a multiple
field technique with optimization of beam entry direction
and beam weights in order to achieve a homogenous dose
to planning target volume and minimize dose to organs at
risk. Field shaping using a multi leaf collimator was used.
For tumours located at or above the level of carina, the
caudal border of the clinical target volume was 5 cm
below diagnosed tumour, whereas the supraclavicular
nodes defined the cranial border. For tumours located
below the carina, the cranial border of the clinical target
volume included 5 cm of radiographically uninvolved
esophagus while the coeliac lymph nodes defined the cau-
dal border, down to upper part of L1. In lateral, anterior
and posterior directions clinical target volume encom-
passed gross tumour volume and the paraesophageal area
with a margin of 1 cm but not including anatomical bar-
riers as pleura, pericardium or bone. Dose–volume data of
the heart including the pericardium with exclusion of the
great vessels were extracted from individual dose distri-
bution data in the treatment planning system. Planning
target volume receiving >95% of planned radiation dose
(PTV > 95%) all well as planning target volume receiving
95–105% of planned dose (PTV 95–105%) was measured.
The percentage of the heart volume receiving 10 Gy or
more (V10) and 30 Gy or more (V30) was measured. V30
was minimized as much as possible according to protocol.
Surgery was scheduled 4–6 weeks after completion of
neoadjuvant treatment.
Echocardiography
Strain is a validated, relatively new, echocardiogra-
phic parameter for assessment of left ventricular
function [19-21]. Strain gives an average of longitu-
dinal shortening in the distance between individual
speckles (natural acoustic markers) in the selected
view of the ventricle. Global strain (GS) is thus the
average strain of segments obtained from one projec-
tion. GS was chosen as the primary outcome param-
eter in this study as it is considered more sensitive
for measuring left ventricular function and not as user
dependent as EF [22] [23,24]. Other echocardiographic
parameters were chosen in accordance with European
Association of Echocardiography guidelines [25]. For re-
gional function we measured atrioventricular movement
using tissue Doppler, a robust parameter sensitive to
early impairment of left ventricular longitudinal systolic
function [26].Echocardiography was performed before start of neo-
adjuvant therapy and repeated 4–6 weeks after com-
pletion of neoadjuvant therapy. A Vivid 7 ultrasound
scanner (GE Vingmed, Horten, Norway) and a standard
2.5 MHz transducer were used. All but three exams were
performed by the same laboratory technician according
to research protocol. Post processing analysis was per-
formed by a single analyser, ML, using Echo PAC (GE
Vingmed, Horten, Norway) according to the manufac-
turer’s instructions. Both the echocardiography examiner
and interpreter were blinded to study group allocation.
All exams were interpreted after inclusion was closed.
A standard cardiac exam was performed on all subjects.
One or more loops of three heartbeats were recorded
online for each view and the best cardiac cycle selected for
analysis during post processing. EF was calculated accord-
ing to Simpson biplane. Mitral inflow was measured using
pulsed wave Doppler. Peak velocity in the early rapid
filling phase when the ventricle relaxes (E-Wave) and peak
velocity of the late filling due to atrial contraction (A-
Wave) were measured by pulsed Doppler across the mitral
valve during diastole. Strain was measured using tissue
tracing analysis in the apical four-chamber view centred
on the left ventricle. For GS analysis a single cycle was
used and all analyzed segments were approved by the pro-
gram as well as by the analyzer. Tissue Doppler-based
tissue tracing was used to measure atrio-ventricular
plane movement. Mitral annular plane systolic excur-
sion (MAPSE) was measured as the median value of
three heart cycles using a region of interest (ROI) of
6×6 mm in the basal septum (sept) and basal antero-
lateral (lat) wall (Figure 1). Pictures were adjusted for
optimal resolution and alignment of cardiac walls with the
ultrasound beam.
NT-proBNP
Venous blood was collected in EDTA tubes before neoad-
juvant treatment and on admission for surgery 4–6 weeks
after neoadjuvant therapy. Electrochemiluminescence im-
munoassay with Modular Analytics E170 (Roche Diag-
nostics, Mannheim, Germany) was used for the analyses,
which were all performed by the Karolinska University
Hospital accredited laboratory for clinical chemistry.
Exercise test
Exercise tests of maximum work capacity measured in
Watts were completed on a bicycle ergometer under the
supervision of a dedicated staff member of an accredited
physiology department. Maximum capacity was deter-
mined when patients were unable to maintain 60 revolu-
tions per minute due to either, fatigue, shortness of breath
or chest pain. The test could also be stopped by the staff
due to the occurrence of arrhythmias, electrocardiogram
changes or pathological blood pressure reactions. Testing
Figure 1 Echocardiographic measurements. Schematic illustration of echocardiographic measurements from apical four-chamber view. EF,
ejection fraction measured according to Simpson Biplane; EDV, end diastolic volume; ESV end systolic volume; MAPSE, mitral annular plane systolic
excursion; GS, global strain; E and A denotes blood velocities over the mitral valve during diastole.
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at the patient’s referring hospital.
Statistics
Data were analyzed as intention to treat using a linear
mixed model analysis for repeated measures data. The
model was used to analyze the effects of within-group
change and the interaction between groups. This was
defined as the basic model. In addition to the basic
model, the influence of different covariates and factors
was analyzed. The group effect was the difference between
radiotherapy and chemotherapy, and the trend effect was
the change between the first measure and the second
measure. The within-group change was the difference
between the first and second measure in respective
groups. The interaction effect was the difference in
change between groups. The covariance structure used
in the models was unstructured. Before performing ana-
lyses, tests of normal distribution were performed and
log transformation was performed for non-parametric
data. Due to the small data set, several mixed models
analyses were performed and in each analysis one of a
set of covariates was added to the basic model to test
for any impact on the results. The set of covariates was
gender, age, BMI, ASA classification, hypertension, is-
chemic heart disease, smoking, chronic obstructive pul-
monary disease, anemia, diabetes, and alcohol abuse.
The Bonferroni correction was used to account for mul-
tiple comparisons. Patient characteristics are presented
as median (range) and data regarding heart function as
mean (95% confidence interval). Subject characteristics
were analyzed using 2-tailed Mann Whitney U test and
2-tailed Fisher’s exact test as appropriate.Results
Patient characteristics
A total of 40 patients participated in the study (Figure 2).
There were no statistically significant differences between
the study groups regarding demographic and disease-
specific characteristics as seen in Table 1. Six patients,
(two in the chemoradiotherapy group) did not complete
neoadjuvant treatment due to adverse events, persisting
neutropenia in three cases, renal failure in one, peripheral
neuropathy (foot drop) in one and circulatory instability
in one. Five patients (two in the chemoradiotherapy
group) had a reduced chemotherapy dose due to side
effects. One patient had a reduced radiation dose due to
thoracic pain. Target radiation dose was achieved in all
other patients as shown by >95% and PTV 95–105%. Me-
dian PTV >95% was 99% (range 96–100%) and median
PTV 95–105% was 97% (range 83–100%). Radiation dose
to the heart was defined by V10 and V30. Median V10 to
the heart was 74.9% (range 50.0–92.2%) and median V30
was 29.0% (range 0–80.1%).
Echocardiography
Echocardiographic parameters were similar between
groups before the start of neoadjuvant treatment. The
neoadjuvant treatment induced no change in GS or EF
in either of the groups (Table 2). MAPSE sept decreased
significantly in the chemoradiotherapy group (mean
change −1.4 mm, CI −2.4, −0.5, p = 0.02) and there was
a trend towards an interaction effect (p = 0.09). E/A
ratio in the chemoradiotherapy group also decreased
significantly (mean change −0.22, CI −0.4, 0.1, p = 0.005)
due to a significant decrease in E velocity (mean
change −14.7 cm/s, CI −23.8, −5.8, p = 0.03) coupled
Assessed for eligibility (n=111)
Excluded  (n=56)
• Not meeting inclusion criteria (25)
• Declined to participate (26)
• Other reasons (5)
• Pre neoadjuvant TTE performed (12)
• Pre neoadjuvant TTE not performed (11)
• Logistical reasons (9)
• Geographical reasons (2)
Randomized (n=55)
• Post neoadjuvant TTE performed (17)
• Post neoadjuvant TTE not performed (6)
• Logistical reasons (2)
• Declined (2)
• Died (1)
• Disease progress (1)
• Post neoadjuvant TTE performed (14)
• Post neoadjuvant TTE not performed (3)
• Died (1)
• Disease progress (2)
• Pre neoadjuvant TTE performed (10)
• Pre neoadjuvant TTE not performed (7)
• Logistical reasons (5)
• Geographical reasons (2)
• Surgery not planned on Karolinska (13)
• Transhiatal surgery planned (1)
Excluded due to erroneous enrolment 
(renal failure; n=1)
Underwent neoadjuvant chemotherapy 
(n=23)






Analyzed Linear Mixed Models
(n=23)
Analyzed Linear Mixed Models
(n=17)
Figure 2 Patient flow chart. Flow chart of screened, enrolled and analyzed patients.
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CI −7.1, 10.7, p = 0.98). A trend towards an interaction
effect was found for E velocity (p = 0.09) but not for
E/A (p = 0.39). Adding the covariates gender, age,
BMI, ASA classification, hypertension, ischemic heart
disease, smoking, chronic obstructive pulmonary dis-
ease, anemia, diabetes and alcohol abuse to the
model did not change the results significantly. See
also Figure 2a-b in the additional file for scatterplots
[Additional file 1]. No dose–response relationship was
found between V30 and the echocardiographic changes
(data not shown).
NT-proBNP
After neoadjuvant treatment we observed a significant in-
crease of NT-proBNP in the chemoradiotherapy group
(mean 140%, CI 27–357%, p = 0.05), but no significant
change after chemotherapy (mean 14%, CI 1–82%, p > 0.99)
and a trend towards an interaction effect (p = 0.07)(Table 2). The addition of the covariates listed above did
not change results significantly. See also Figure 2c in
the additional file for scatterplot [Additional file 1]. No
dose–response relationship was found between V30 and
the NT-proBNP changes (data not shown).
Exercise test
All tests were stopped by the patient due to fatigue or
shortness of breath without indications of cardiac ische-
mia. Both neoadjuvant regimens were followed by a sig-
nificant decrease in the patients working capacity (p = 0.03
and p = 0.001, respectively). This decrease was more
pronounced in the chemoradiotherapy group (mean
change −33 W, CI −48, −18 vs −17 W, CI −29, −5)
but the interaction effect did not reach significance
(p = 0.10) (Table 2). The addition of the covariates
listed above did not change results significantly. See




Variable Pre neoadjuvant Post neoadjuvant Pa
EF (%) 59 (56–62) 57 (53–60) >0
GS (%) −17.6 (−16, −19) −15.7 (−14, −17) 0.2
MAPSE sept (cm/s) 12.5 (11.5–13.5) 12.1 (11.2–13.1) >0
MAPSE lat (cm/s) 11.5 (10.4–12.6) 11.2 (10.2–12.3) >0
E (cm/s) 72.0 (62.6–81.4) 68.1 (62.2–74.1) >0
A (cm/s) 67.8 (58.2–77.5) 74.6 (63.9–85.3) 0.3
E/A 1.08 (0.93–1.25) 0.95 (0.81–1.10) 0.4
NT–ProBNP (ηg/l) 93 (58–149) 108 (70–167) >0
Exercise test (W) 150 (135–165) 133 (115–151) 0.0
Data are presented as mean (95% confidence interval). aMixed models test of withi
GS, global strain; MAPSE, mitral annular plane systolic excursion; NT-proBNP, N-term








62 (46–71) 66 (56–75) 0.09
Male/Female 19/4 15/2 1.00
BMI median (range) 23 (18–33) 26 (21–35) 0.06
Weight change kg
median (range)




16 (70) 13 (76) 0.73
Squamous-cell
carcinoma, n (%)
7 (30) 4 (24) 0.73
Clinical T stage
T1 0 0 _
T2 9 4 _
T3 14 13 _
Clinical N stage
N0 5 3 >0.99
N1 18 14 >0.99
Cardiovascular
disease, n (%)
7 (30) 10 (59) 0.11
Hypertension, n (%) 7 (30) 9 (53) 0.20
Ischemic heart
disease, n (%)
1 (4) 2 (12) 0.56
Smoking ongoing
or previous, n (%)
10 (43) 4 (24) 0.32
COPD, n (%) 5 (22) 1 (6) 0.22
Anemia, n (%) 6 (26) 4 (23) 1.00
Diabetes, n (%) 3 (13) 3 (18) 1.00
ASA class, n I/II/III/IV 0/15/8/0 0/10/7/0 0.75
BMI, Body mass index; COPD, chronic obstructive pulmonary disease; ASA,
American Society of Anesthesiologists.
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Cardiac effects of neoadjuvant chemoradiotherapy in the
treatment of cancer of the esophagus or GE-junction are
important as they could have direct implications on
anesthetic management and postoperative management
as well as imply a need to individualize neoadjuvant
treatment. This study provides results indicating that
neoadjuvant chemoradiotherapy for cancer of the esopha-
gus or GE-junction induces an acute impairment of heart
function whereas neoadjuvant chemotherapy does not. Al-
though we did not find any effect on our primary outcome
variable global strain, a small but statistically significant
decrease in septal function, was observed after chemora-
diotherapy. The septum receives the highest radiation
doses during chemoradiotherapy for esophageal cancer as
shown by Hatakenaka et al. using magnetic resonance
imaging [10]. In that study, regional wall motion was
decreased for the mid anteroseptal, mid inferoseptal and
mid inferior segments, which is in accordance with our
findings. Moreover, in the study by Hatakenaka the largest
decrease in wall movements was observed in the palliative
patients who received the highest radiation doses indicat-
ing a dose-dependent response. Two retrospective studies
have shown a decrease of EF after chemoradiotherapy
using different combinations of chemotherapeutic agents
and again using higher radiation doses (45–50 Gy) [11,27].
We were unable to show an effect on global systolic func-
tion, which may either be related to our small sample size
or to the use of lower radiation doses.
Chemoradiotherapy also decreased the blood flow
velocities over the mitral valve during the fast, passive
filling phase of the left ventricle (E), coupled with an
unchanged blood flow during atrial contraction (A) and
accordingly a decreased E/A. These data suggest an im-
paired diastolic function as a consequence of impaired
relaxation of the left ventricle. Hatakenaka and coworkers
also reported an impairment of left ventricular relaxation
after radiotherapy [10].Chemoradiotherapy
Pre neoadjuvant Post neoadjuvant pa pb
.99 60 (57–64) 59 (55–63) >0.99 0.80
6 −17.3 (−16, −19) −16.1 (−14, −18) >0.99 0.59
.99 12.6 (11.4–13.8) 11.1 (10.1–12.2) 0.02 0.09
.99 11.2 (10.0–12.4) 11.0 (9.8–12.1) >0.99 0.96
.99 78.8 (68.4–89.3) 64.1 (57.2–70.9) 0.01 0.09
7 82.0 (71.1–92.7) 83.7 (71.6–95.9) 0.98 0.41
3 0.97 (0.82–1.14) 0.77 (0.65–0.92) 0.03 0.39
.99 65 (32–130) 154 (92–260) 0.05 0.07
3 151 (133–151) 118 (96–140) 0.001 0.10
n-group changes; bMixed models test of interaction effect; EF, ejection fraction;
inal pro-brain natriuretic peptide.
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proBNP. This biomarker has been studied as a predictor
for the risk of perioperative cardiac complications with
cutoff values between 201–791 ηg/ml being suggested
[28,29]. Pre and perioperative levels of NT-proBNP are
also strong predictors for atrial fibrillation even if cutoff
levels are under debate [30].
We were unable to demonstrate a dose–response rela-
tionship between V30 and the echocardiographic changes
or NT-proBNP levels. This may be due to the small num-
ber of patients enrolled but also dependent on the fact
that V30 reflects the radiation dose targeting the whole
heart rather than different segments. We refrained from
doing a segmental analysis since this would require a
larger dataset.
The clinical relevance of our findings is unclear. The
level of systolic impairment detected was small and
probably not clinically significant in a patient with an
otherwise well-functioning left ventricle. Diastolic changes
were larger with mean E/A levels after neoadjuvant ther-
apy reaching grade I diastolic dysfunction which could
have clinical implications. NT-proBNP levels increased
following chemoradiotherapy and might indicate an in-
creased risk for postoperative cardiac events and atrial
fibrillation. This also shows that repeated NT-proBNP
measurements could be a simple method to describe im-
pairment from neoadjuvant treatment in future studies.
Preoperative working capacity, as assessed during an exer-
cise test, trajects into perioperative risks after esophagec-
tomy [31,32]. We also observed that currently practiced
neoadjuvant therapies, decreased the work capacity
significantly in both groups. The effect was more pro-
nounced in the chemoradiotherapy group but there
was no significant interaction effect.
Cisplatin and 5-fluorouracil are commonly used drugs
in chemotherapy regimens for esophageal cancer. These
drugs are known to be associated with cardiotoxic side
effects [33]. Therefore it was interesting to note that we
were unable to detect echocardiographic or biochemical
signs of decreased left ventricular function from chemo-
therapy alone.
The question whether neoadjuvant chemoradiotherapy
is associated with an increased risk of postoperative
morbidity compared with chemotherapy remains unre-
solved [5,7]. Only two previous randomized trials (n = 74
and n = 119) have directly compared neoadjuvant chemo-
therapy versus chemoradiotherapy [2,3]. However, func-
tional studies of the heart were not a part of any of these
prospective protocols.
Impaired left ventricular systolic and diastolic function
following neoadjuvant chemoradiotherapy could well have
a bearing on the incidence and grade of the innately high
postoperative cardiovascular and pulmonary morbidity
after esophagectomy. Taken together our data emphasizethe relevance of dedicated studies aimed at further clarify-
ing the details and consequences of the cardiotoxicity of
current chemoradiotherapy regimens. One pathway that
needs to be explored is cardiovascular function during the
perioperative period.
One important limitation of our study is the small
sample size, where the cases represented a cohort of pa-
tients consecutively enrolled from a larger, multicenter,
randomized study. Two issues emerge as a consequence
of this: the power of the observations and the possibility
of selection bias. It should however, be emphasized that
Karolinska University Hospital was the largest including
center and the patients in our cohort represent 23% of
the total study population. The randomization was not
stratified to each center which may explain the small
difference in the size of the treatment groups. There
were no statistical differences in comorbidities between
the study groups and the subsequent analysis of the effects
of comorbidities in the linear mixed models did not dis-
play any significant impact on the results. Work capacity
was also similar between the groups before neoadjuvant
treatment suggesting comparable patients groups.
The second limitation, which we tried to confront, was
the missing values within our cohort. The design of the
present clinical study was very complex in a logistic per-
spective, in that we were faced with a short timeframe
during which we had to plan and complete the echocar-
diographic examinations, i.e. from the randomization to
the start of neoadjuvant treatment. During this limited
time frame several other investigations and procedures
(central lines for chemotherapy, PET-CT, endoscopic
ultrasonography, respiratory and exercise test) had to
be performed, usually at other hospitals. In addition,
we chose to concentrate the echocardiography investiga-
tions at the tertiary referral center to increase the validity
of the echocardiography. In order to partially compensate
for the impact of missing data we adopted a linear mixed
model statistics where the patients were analyzed as in-
tention to treat. Linear mixed models give the opportunity
to analyze all available data and not having to exclude
cases where the dataset is incomplete. It also gives the
option to correct for co-variables and is not restricted to a
spherical or compound symmetry where we rely on the
assumption that data are missing at random. By doing this
we were able to mitigate some of the impact of missing
data and further explore how patient comorbidity affected
the results. No effect was found.
Conclusions
Neoadjuvant chemoradiotherapy seems to induce a slight
acute impairment of both systolic and diastolic left ven-
tricle function, whereas chemotherapy does not. The sys-
tolic impairment was small and probably not clinically
significant in a patient with an otherwise well-functioning
Lund et al. Radiation Oncology  (2015) 10:16 Page 8 of 9left ventricle. The change in diastolic function was larger
and might have clinical implications. These effects of che-
moradiotherapy may enhance the risk of postoperative
morbidity and should be taken into clinical consideration
in patients with cardiac comorbidity. Corresponding and
related effects on the heart need to be further explored in
future studies of neoadjuvant chemoradiotherapy for
cancer of the esophagus and GE-junction.
Additional file
Additional file 1: Scatterplots of MAPSE lat, E, NT-proBNP and
exercise capacity are shown. All data are plotted with lines connecting
paired measurements.
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